June 2025 highlights groundbreaking advancements in endocrinology, featuring key insights from major conferences on diabetes, heart health, and kidney care.
Patrick Campbell
Advertisement
Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy.
Follow him on Twitter @RealPatCampbell or reach him via email at [email protected].
Articles by Patrick Campbell
Our June 2025 recap highlights significant advancements in cardiology, including new drug approvals and pivotal trial results.
Discover groundbreaking FDA approvals in 2025 that redefine treatment standards, enhance patient care, and address critical public health needs.
Mifepristone shows promise in improving glycemic control and reducing weight in patients with hypercortisolism and type 2 diabetes.
Maridebart cafraglutide shows potential as a monthly treatment for obesity and type 2 diabetes, demonstrating significant weight loss and glycemic improvements.
A new study reveals once-weekly efsitora alfa effectively lowers blood glucose in type 2 diabetes.
A global study reveals that universal access to semaglutide could save 28 million lives and significantly reduce obesity and diabetes worldwide.
CagriSema shows weight loss results in recent trials comparable to existing interventions.
A phase 3 trial reveals ecnoglutide significantly reduces body weight in overweight patients, showcasing its potential as a novel obesity treatment.
New findings reveal semaglutide significantly enhances walking ability and quality of life for patients with T2D and PAD.
A new study reveals hybrid closed-loop technology significantly improves glucose control for pregnant women with T1D.
Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.
The ACHIEVE-1 trial reveals orforglipron's potential as a breakthrough treatment for type 2 diabetes.
New research reveals amycretin's promising potential for weight loss in obesity treatment, advancing to phase 3 trials for effective management options.
The FDA-cleared DermaSensor shows promise for skin cancer detection in primary care.
A recap of 3 Kidney Compass podcast episodes recorded at ERA 2025, including summaries and preview clips.
A recap of 5 studies to know from the ERA 2025 Congress, including expert perspectives.
A recent meta-analysis reveals GLP-1 RAs significantly reduce adverse kidney outcomes, highlighting their potential in chronic kidney disease management.
Prespecified analysis of 320 patients in VISIONARY were presented at ERA 2025 Congress.
Combination therapy with finerenone and empagliflozin significantly reduces urinary albumin levels in CKD patients.
New 100-week data reveals zigakibart's significant efficacy and safety in reducing proteinuria for IgA nephropathy.
Get an overview of the top stories from May 2025 in endocrinology in our monthly recap!
An overview of the 7 presentations included as late-breaking clinical trials at ERA 2025.
Discover key advancements and setbacks in cardiovascular medicine from May 2025, shaping the future of cardiometabolic care and treatment options.
The May 30, 2025 SOCS News Update highlights cosmetic concerns among patients with skin of color.
New data reveal tirzepatide significantly outperforms semaglutide in weight loss.
Data from nearly half a dozen trials suggests steroidal MRAs may provide little benefit in kidney transplant patients.
The study evaluated more than 450 patient visits and concluded AI decision support could improve adherence to guideline-adherent care recommendations.
The Best Practice Advice is aimed at detailing benefits and harms of cannabis or cannabinoids in the management of chronic noncancer pain.
A recap of 10 clinical trials in cardiovascular care to know from the American College of Cardiology 2025 Scientific Sessions.
Advertisement
Advertisement
Advertisement
Trending on HCPLive
1
GLP-1 Initiation Associated With Increase in Hypotensive Events in Patients With Hypertension
2
Weight Loss Improves Cardiometabolic Biomarkers in Digital Metabolic Reset Program
3
How to Counsel Patients About Skincare Safety, Sunscreen Safety, and Product Ingredients
4
GLP-1 RAs Show Renal, Survival Benefits in Kidney Transplant Recipients With Type 2 Diabetes
5